Skip to main content

Table 3 Proportion of patients with LDAS* or remission at baseline and at Month 6 for second line abatacept stratified by 1 or ≥2 prior anti-TNF agent

From: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

Measure Remission at month 6 LDAS* at month 6
  N Percent (95% CI) N Percent (95% CI)
   One previous anti-TNF   
DAS28 (ESR) 245 15.9 (11.3, 20.5) 245 29.8 (24.1, 35.5)
DAS28 (CRP) 57 22.8 (11.9, 33.7) 57 42.1 (29.3, 54.9)
CDAI 289 5.2 (2.6, 7.7) 289 35.6 (30.1, 41.2)
   ≥2 previous anti-TNFs   
DAS28 (ESR) 234 12.8 (8.5, 17.1) 234 25.6 (20.0, 31.2)
DAS28 (CRP) 75 17.3 (8.8, 25.9) 75 33.3 (22.7, 44.0)
CDAI 286 4.9 (2.4, 7.4) 286 28.3 (23.1, 33.5)
  1. *LDAS includes patients in remission (DAS remission: <2.6; CDAI remission: ≤2.8).
  2. CDAI, Clinical Disease Activity Index; DAS, Disease Activity Score; LDAS, Low Disease Activity Score (≤3.2 for DAS and ≤10 for CDAI).